| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.042 | 0.8 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |